reason report
better expect posit revis go
bottom line abbvi solid result driven better-
than-expect perform erod product continu
strong growth oncolog product driver like
close scrutin see whether off-set continu
rapid eros humira ex us market biosimilar given
posit result approv posit comment
skyrizi launch psoriasi increas
revenu forecast compani beyond
ep estim increas
chang increas price target maintain
market perform rate year revenu result still like
rel flat compar last year although benefit
share repurchas disciplin expens control
view seem like gener high-singl low-double-digit ep
growth year
today market open report result consist
revenu beat ep beat versu consensu
increas ep guidanc consensu
top-lin beat driven less biosimilar/gener eros ex-
us humira androgel rather sustain out-performance
key product would lead upward revis long-term estim
ex-u humira strength would normal reward
market coupl posit news formal guidanc
product geographi consensu
head quarter remaind year benefit
improv profit potenti rapid growth skyrizi
psoriasi help keep revenu flat prior year
period signific loss exclus increas
revenu ep estim still
consensu ep new price target
continu expect range-bound stock perform
maintain mp
previous cover highlight
confer call recap note link
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm dilut ep includ option expens present
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target per share stock rate market perform
transit corpor ownership success larg independ
biopharmaceut compani mani best featur biotech pharma
resourc expertis infrastructur diversif larg pharma competitor
specialti product profil matur biotechnolog compani remain highli depend
singl franchis humira sale total sale suggest
us valuat still discount compar diversifi peer
multipl settlement us biosimilar entrant postpon eros brand domest
eros europ underway appear sharper faster prior
product abbvi abil control destini may fade depend action
new entrant even us would surpris see pressur humira
growth new entrant chang regul legal oversight manag care
pbm contract still expect oncolog product imbruvica venclexta becom
signific product gener revenu
compani hcv product maintain roughli pariti share competitor
look compani array promis late-stag clinic medicin
inflamm metabol diseas struggl expand oncolog franchis beyond
imbruvica venclexta year flat revenu growth current pipelin
establish product contribut single-digit revenu growth
unlik off-set massiv headwind face biosimilar enter market compet
humira
ex-u humira androgel contribut top-lin
abbvi total product revenu consensu
estim abbvi revenu declin sequenti annual global humira
sale declin sequenti consensu
line forecast
us humira revenu grew y/i primarili demand line consensu
forecast meanwhil ex-u humira revenu declin q/q
beat consensu estim annual ex-u humira declin
oper declin us imbruvica sale declin sequenti
consensu forecast abbvi
row profit share imbruvica grew q/q consensu
abbvi hcv revenu quarter viekira mavyret declin sequenti
us ex-u us hcv revenu came consensu estim
expect row hcv revenu came consensu
estim expect
also benefit androgel sale better anticip face
gener entri androgel sale consensu expect
also report higher product revenu includ initi
sale orilissa
lower expens share count reduct contribut ep
total non-gaap expens less consensu estim
driven primarili lower product sell cost disclos gross margin
benefit y/i reduct humira royalti owe result oper
margin larg increas increas
abbvi tax rate line consensu share count decreas
sequenti annual report non-gaap ep
consensu estim non-gaap ep grew annual
ebit grew annual realist reflect underli busi perform
provid revenu guidanc compar consensu pro
forma ep compar consensu revenu guidanc contempl
fx headwind also provid sale guidanc us humira growth ex-
us humira global imbruvica
manag also suggest oper margin compar flag
higher sg anticip associ new product launch final
adjust tax rate expect line full-year guidanc
increas full-year guidanc consensu
increas select element guidanc increas adjust ep
guidanc modestli consensu midpoint
compani also updat two element detail guidanc includ gross
margin approach prior oper margin surpass
prior remain product guidanc guidanc left unchang
year commerci catalyst clinic catalyst
abbvi catalyst flow larg commerci rather clinic consensu estim
like revis incorpor initi launch quarter orilissa
skyrizi upadacitinib well launch commentari manag
alreadi suggest skyrizi orilissa contribut revenu
respect meet surpass inform guidanc estim
skyrizi orilissa like increas
biggest catalyst regulatori event surround upadacitinib
compani inhibitor rheumatoid arthriti ra autoimmun diseas
like includ fda advisori committe adcomm meet initi ra approv
agenc decis label upadacitinib estim surpass investor
look broad adcomm support label avoid black warn thromboembol
cardiovascular risk disclos pdufa date upadacitinib
compani use prioriti review voucher regulatori submiss
call also highlight mid- late-stag program investor follow
includ anti-egfr epiderm growth factor receptor antibodi drug conjug
depatuxizumab mafodotin formerli phase result newly-
diagnos glioblastoma multiform gbm sometim also advanc
bcl inhibitor myelofibrosi solid tumor novel immuno-oncolog antibodi
glycoprotein repetit predomin licens argenx tnf steroid
year american societi clinic oncolog partner roch also
report phase result trial venclexta/gazyva frontlin chronic lymphocyt
leukemia cll announc data select fda real-tim
oncolog review program could expedit approv process supplement drug
model updat captur quarterli trend bullish skyrizi outlook pt
follow result guidanc chang revis revenu earn
forecast better reflect compani outlook biggest chang skyrizi
increas probability-of-success last tuesday fda approv
also increas psoriasi estim mirror launch novarti cosentyx base
abbvi guidanc launch ramp significantli histor psoriasi ramp
skyrizi estim increas result chang
also updat estim sever product decreas forecast
humira also reflect faster ex-u price
eros also increas revenu imbruvica given strong volum
sale trend well recent label expans cll forecast hcv decreas
chang biggest chang
synagi estim decreas increas androgel estim
doubl captur abil hold share market face gener
total revenu forecast increas
updat total revenu forecast line consensu
consensu forecast top-lin growth compound-annual-growth-rate year
flat sale
increas estim oper margin percentag point
flat forecast expens still assum signific growth
decreas estim given impress expens
control far year also dial back expect share repurchas
program pro forma dilut ep forecast higher
higher consensu pro forma dilut ep
consensu net result adjust
chang sector valuat multipl bring price target previous
price target base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar larg biopharmaceut compani price sale multipl
larg cap peer compani stock discount cash flow dcf appli peer ep
revenu multipl use averag larg cap larg molecul therapeut compani mid-
term growth tail risk celg averag consensu
ep multipl appli current ep estim give valu
use revenu multipl similar compani consensu
sale appli revenu estim give valu
lastli dcf valuat given wacc termin cash flow growth rate
begin humira biosimilar entri give present valu averag
three method current price target
risk view outlook valuat includ major chang price
outlook reimburs coverag label competit posit humira compani
main product risk includ commerci develop disappoint compani
follow-on program inflammatori diseas imbruvica venclexta expand
hematolog malign well competit posit compani next-
gener hcv therapi also compani remain highli lever commit grow
dividend reduct forecast ebitda due neg busi trend would place
compani capit alloc strategi dividend growth risk opportun upsid
expect includ stronger-than-expect price volum share humira
emerg tangibl demand underappreci element compani early-to-
mid stage pipelin asset potenti label expans opportun late stage opportun
non-gaap cost good sold
interest expens
abbvi guidanc
svb leerink llc research compani file zack factset consensu
svb leerink llc research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
bispecif mab i/o rova-t non-rova-t
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
brand chemic name
type event
event trial detail
date known
specifi
up/down
svb leerink view
cll trial front-lin cll
phase trial reuslt newly-diagnos
supplementari approv cll result front-
phase trial front-lin aml
svb leerink llc research compani file
analysi stock price svb leerink target
method price base current larg cap hc stock mid-term growth tail risk
ep multipl appli ep celg
svb leerink forma ep estim
method present valu base price sale multipl peer larg cap biopharma stock
averag price sale larg cap biopharma multipl
impli market cap mm estimate sale
anticip share count mm
method leerink probabl adjust dcf adjust net wacc termin
current svb leerink dcf marketed/l stage program
sourc svb leerink llc estim compani file factset
